Просмотр новости
Найдите то, что Вас интересует
Спутники
РН
SpaceX
Роскосмос
NASA
Epigenetics Market by Product (Kit [Antibodies, Reagents], Enzyme), Service (Single-Cell Epigenomics, Multi-omics), Method (DNA Methylation, Histone Modification), Technique (NGS, PCR, MS), Application (Oncology, Immunology, CVD) - Global Forecast to 2031..., Market Research Report: MarketsandMarkets
Дата публикации: 26-06-2026 00:00:00
Основное содержимое страницы с новостью.
Epigenetics Market by Product (Kit [Antibodies, Reagents], Enzyme), Service (Single-Cell Epigenomics, Multi-omics), Method (DNA Methylation, Histone Modification), Technique (NGS, PCR, MS), Application (Oncology, Immunology, CVD) - Global Forecast to 2031
USD 3.92 BN
MARKET SIZE, 2031
EPIGENETICS MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global epigenetics market is projected to grow from USD 2.22 billion in 2026 to USD 3.92 billion by 2031, at a CAGR of 12.0% during the forecast period. The market was valued at USD 2.10 billion in 2025. The growth of the epigenetics market is driven by increasing adoption of epigenomic profiling technologies, rising demand for DNA methylation analysis, expanding use of NGS-based workflows, and growing application of epigenetics in oncology, precision medicine, drug discovery, and biomarker research. Wider use of ChIP-seq, ATAC-seq, PCR & qPCR, mass spectrometry, and methylation arrays is supporting epigenetic analysis across research, translational, and clinical settings. Additionally, growing focus on liquid biopsy-based methylation biomarkers, single-cell epigenomics, multi-omics integration, and AI-enabled data interpretation is boosting demand for kits & reagents, enzymes, instruments, software, and epigenetic profiling services across the market.
KEY TAKEAWAYS
-
By Region
North America accounted for the largest share of 41.7% of the epigenetics market in 2025. Growth in this region is driven by strong genomics and biomedical research infrastructure, high adoption of NGS-based epigenomic profiling, sustained investments in oncology and precision medicine, and the presence of leading sequencing, molecular biology, and bioinformatics companies.
-
By Product
By product, kits & reagents accounted for the largest share of the epigenetics market in 2025. This dominance is driven by their frequent use across DNA methylation analysis, ChIP workflows, bisulfite conversion, CUT&RUN/CUT&TAG assays, histone modification studies, sample preparation, and downstream PCR or sequencing-based epigenetic profiling.
-
By Method
By method, DNA methylation accounted for the largest share of 56.2% of the epigenetics market in 2025. This is attributed to its broad use in cancer research, biomarker discovery, promoter methylation analysis, tumor classification, liquid biopsy testing, and disease risk assessment across research, translational, and clinical settings.
-
By End User (Product)
By end user, academic & research institutes accounted for the largest share of 45.9% of the epigenetics products market in 2025. This dominance is driven by extensive use of epigenetics products in gene regulation studies, chromatin biology, developmental biology, oncology research, neuroscience, immunology, and early-stage biomarker discovery.
-
Competitive Landscape - Key Players
Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), and Merck KGaA (Germany) were identified as some of the star players in the epigenetics market, given their strong market share and offering footprint.
-
Competitive Landscape - SMEs/Startups
EpiCypher (US), Fios Genomics (UK), GenomeScan (Netherlands), Creative Biogene (US), and BPS Bioscience, Inc. (US), among others, have distinguished themselves among startups and SMEs by securing a strong foothold in niche areas, underscoring their potential as emerging market leaders.
The epigenetics market is growing due to the increasing adoption of NGS-based epigenomic profiling, rising focus on precision medicine and biomarker research, expanding use of DNA methylation analysis in oncology and diagnostics, and continuous advancements in single-cell epigenomics, multi-omics integration, and epigenetic data interpretation.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The epigenetics market is shifting from conventional, assay-specific workflows toward high-throughput, integrated, and clinically relevant epigenomic profiling platforms. Adoption of NGS-based methylome profiling, 5-base and native DNA methylation sequencing, single-cell ATAC-seq, CUT&Tag, CUT&RUN, and liquid biopsy methylation assays is increasing, enabling deeper insights into gene regulation, tumor biology, disease risk, and therapeutic response. Additionally, growing demand for low-input, high-sensitivity profiling, reproducible antibodies, validated kits, and standardized QC workflows is accelerating market growth. Further, integration of epigenetics with single-cell, multi-omics, and AI-driven data interpretation is improving biomarker discovery, patient stratification, and translational evidence generation, while outsourced epigenomics services are supporting faster turnaround and broader adoption across drug discovery, diagnostics, and precision medicine applications.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
OPPORTUNITIES
Impact
Level
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Declining sequencing costs and faster turnaround times are accelerating the adoption of epigenetic analysis across research and translational settings. Lower per-sample costs make genome-wide DNA methylation, ChIP-seq, ATAC-seq, and chromatin profiling more accessible to academic institutes, pharmaceutical companies, CROs, and clinical laboratories. Faster sequencing enables larger cohort studies, quicker biomarker validation, and smoother integration with multi-omics workflows, supporting wider use in oncology, precision medicine, and drug discovery.
The application of epigenomic data in toxicology remains limited due to challenges in interpretation, validation, and regulatory acceptance. Epigenetic changes are dynamic and influenced by tissue type, exposure duration, and environmental conditions, making toxicity-linked conclusions difficult to standardize. Limited reference datasets, validated endpoints, and regulatory frameworks restrict broader use in safety assessment workflows.
Emerging applications of epigenetics are creating opportunities across diagnostics, therapeutics, and precision medicine. Epigenetic biomarkers are increasingly used in cancer detection, disease classification, treatment response monitoring, and population screening. Expanding use in metabolic diseases, immunology, cardiovascular disorders, reproductive health, and neurodegenerative research is widening demand for assay kits, sequencing workflows, bioinformatics tools, and profiling services.
Antibody quality remains a key challenge in antibody-dependent epigenetic workflows such as ChIP-seq, CUT&RUN, CUT&Tag, and histone modification studies. Poor specificity, cross-reactivity, batch variability, and weak validation can affect signal quality, reproducibility, and data reliability. These issues increase the need for repeat experiments, assay optimization, and project timeline extensions, as well as overall research costs.
EPIGENETICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Infinium MethylationEPIC v2.0 BeadChip and NGS platforms used for genome-wide DNA methylation profiling in oncology, population studies, biomarker discovery, and precision medicine research | High-throughput methylome analysis | Scalable biomarker discovery | Supports tumor classification and population-level epigenetic studies |
|
|
DNA methylation analysis kits, epigenetic sequencing solutions, antibodies, and PCR/qPCR tools used in targeted methylation detection, ChIP-based studies, and translational epigenetics workflows | Workflow-ready assay tools | Supports PCR and sequencing-based validation | Enables gene regulation and disease research |
|
|
Epigenetic services applied across ChIP-seq, CUT&Tag, ATAC-seq, DNA methylation sequencing, chromatin mapping, IP-MS, and single-cell epigenomics projects | End-to-end outsourced profiling | Reduced in-house workflow burden | Integrated sequencing and bioinformatics support |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The epigenetics market ecosystem comprises product manufacturers, service providers, end users, and regulatory authorities. Product manufacturers, including Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), and Danaher Corporation (US), support the market by supplying kits & reagents, antibodies, enzymes, sequencing reagents, sample preparation products, instruments, and workflow-enabling consumables used in DNA methylation analysis, ChIP-seq, ATAC-seq, histone modification studies, and chromatin profiling. Service providers such as Creative Biogene (US), Fios Genomics (UK), and Novogene Co., Ltd. (China) offer outsourced epigenomic profiling, sequencing, assay support, bioinformatics, and multi-omics data interpretation services. Regulatory authorities, including the US FDA, CDSCO, OLAW, and MHRA, establish requirements related to assay quality, data reliability, research ethics, clinical validation, and compliance. End users, including the University of Cambridge (UK), Amgen Inc. (US), Massachusetts Institute of Technology (US), pharmaceutical companies, biotechnology firms, academic institutes, and clinical research organizations, use epigenetics solutions for oncology research, biomarker discovery, drug development, precision medicine, developmental biology, immunology, and translational research.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
In 2025, kits & reagents dominated the epigenetics market. This leadership is driven by their routine use in DNA methylation analysis, ChIP-based assays, bisulfite conversion, histone modification studies, CUT&RUN/CUT&TAG workflows, sample preparation, and sequencing library preparation. These products are widely used across academic research, pharmaceutical R&D, biomarker discovery, oncology studies, and translational research. Their recurring consumption, assay-specific use, and importance in generating reproducible epigenetic data continue to support steady demand across research and clinical settings.
In 2025, oncology dominated the epigenetics market, supported by the growing use of epigenetic profiling in cancer biology, tumor classification, early detection, treatment response monitoring, and biomarker discovery. DNA methylation, histone modification, and chromatin accessibility studies are widely applied to understand gene regulation changes linked to cancer initiation and progression. The increasing adoption of liquid biopsy-based methylation assays, precision oncology research, and companion diagnostic development further strengthens demand for epigenetics products and services in oncology applications.
In 2025, academic & research institutes dominated the epigenetics products market due to their extensive use of kits, reagents, enzymes, antibodies, and instruments in fundamental and translational research. These institutes widely apply epigenetics tools in gene regulation studies, developmental biology, neuroscience, immunology, cancer research, and biomarker discovery. Strong research funding, growing adoption of NGS-based epigenomic workflows, and increasing focus on single-cell and multi-omics studies continue to drive demand across this end-user group.
EPIGENETICS MARKET: COMPANY EVALUATION MATRIX
In the epigenetics market company evaluation matrix, Thermo Fisher Scientific Inc. (US) is positioned as a star player due to its broad presence across epigenetics products, instruments, and workflow-enabling solutions. The company offers DNA methylation analysis kits, ChIP reagents, histone modification antibodies, enzymes, PCR/qPCR systems, sequencing reagents, sample preparation products, and bioinformatics tools used across methylation profiling, chromatin studies, gene regulation analysis, biomarker discovery, and translational research. Its global reach, strong life sciences customer base, extensive consumables portfolio, and ability to support both routine and advanced epigenetic workflows make it a preferred supplier for academic institutes, pharmaceutical companies, biotechnology firms, CROs, and clinical research laboratories. PacBio (US) is positioned as an emerging leader, supported by its long-read sequencing platforms that enable native DNA analysis, methylation detection, structural variation assessment, and broader epigenomic interpretation. Its focus on high-accuracy long-read sequencing and expanding relevance in complex genome and epigenome studies is strengthening its position in the epigenetics market.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2026 (Value) | USD 2.22 Billion |
| Market Forecast in 2031 (Value) | USD 3.92 Billion |
| Growth Rate | CAGR of 12.0% from 2026-2031 |
| Years Considered | 2024-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
WHAT IS IN IT FOR YOU: EPIGENETICS MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Rest of Europe Breakdown | Country-level market sizing and growth forecasts (Switzerland, Sweden, Turkey, the Netherlands, Norway, Poland, Portugal, Romania, Denmark, Estonia, Finland, the Czech Republic, Greece, Austria, Belgium, and Russia) | Provides granular country-level insights, enabling clients to prioritize high-growth markets |
| Company Evaluation |
|
Delivers visibility into competitors, helping clients identify partners, evaluate positioning, and detect market gaps for smarter collaboration, outsourcing, and strategic market entry decisions |
RECENT DEVELOPMENTS
- January 2026 : Illumina launched Connected Multiomics, a cloud-based research software platform for integrating and visualizing multimodal datasets, including genomics, transcriptomics, proteomics, and epigenetics. This supports downstream analysis of methylation and other epigenomic data with broader multi-omics datasets.
- October 2025 : Thermo Fisher launched SwiftArrayStudio, an integrated microarray analyzer designed to deliver results in as little as 30 hours and reduce hands-on time by up to 40%. The company specifically positioned the platform for future technology needs, including methylation and epigenetics.
- October 2025 : Illumina launched its 5-base solution, enabling simultaneous detection of genomic variants and DNA methylation from a single sample. The workflow combines proprietary 5-base chemistry with DRAGEN algorithms and supports genome/methylome analysis for oncology, rare disease, biomarker discovery, and precision medicine research.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
4
MARKET OVERVIEW
Epigenetics market surges with tech advances, despite data privacy and quality concerns.60
4.2.1.1
DECLINING SEQUENCING COSTS AND TIME
4.2.1.2
GROWING EMPHASIS ON POPULATION-SCALE SCREENING INITIATIVES
4.2.1.3
TECHNOLOGICAL ADVANCEMENTS IN EPIGENETICS RESEARCH
4.2.1.4
RISING DEMAND FOR EPIGENETIC DRUGS AND EPIGENETIC-BASED THERAPEUTICS
4.2.2.1
LIMITED APPLICATIONS OF EPIGENOMIC DATA IN TOXICOLOGY
4.2.2.2
DATA PRIVACY CONCERNS AND SECURITY ISSUES
4.2.3.1
EMERGING APPLICATIONS OF EPIGENETICS
4.2.3.2
INTEGRATION OF MULTI-OMICS
4.2.4.1
CONCERNS REGARDING QUALITY OF ANTIBODIES
4.2.4.2
CHALLENGES ASSOCIATED WITH EPIGENETIC EDITING
4.3
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4
STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Navigate competitive dynamics and pricing shifts in biotech and pharma through strategic ecosystem insights.67
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
BARGAINING POWER OF SUPPLIERS
5.1.2
BARGAINING POWER OF BUYERS
5.1.3
THREAT OF NEW ENTRANTS
5.1.4
THREAT OF SUBSTITUTES
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
5.2
MACROECONOMIC OUTLOOK
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.2.4
TRENDS IN GLOBAL BIOTECH & PHARMA INDUSTRY
5.4.1
ROLE OF PLAYERS IN ECOSYSTEM
5.5.1
AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2023–2025
5.5.1.1
AVERAGE SELLING PRICE TREND, BY INSTRUMENT, 2023–2025
5.5.1.2
AVERAGE SELLING PRICE TREND, BY KITS & REAGENTS, 2023–2025
5.5.2
AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025
5.6.1
IMPORT SCENARIO (HS CODE 9027.50)
5.6.2
EXPORT SCENARIO (HS CODE 9027.50)
5.6.3
IMPORT SCENARIO (HS CODE 3822.00)
5.6.4
EXPORT SCENARIO (HS CODE 3822.00)
5.7
KEY CONFERENCES & EVENTS, 2026–2027
5.8
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.9
INVESTMENT & FUNDING SCENARIO
5.10.1
CFDNA METHYLOME–FRAGMENTOME PROFILING STRENGTHENS MULTICANCER DETECTION
5.10.2
5-BASE NGS WORKFLOW ENABLES INTEGRATED METHYLATION AND VARIANT PROFILING
5.10.3
LONG-READ SEQUENCING SCALES NATIVE EPIGENOME ANALYSIS IN AGING RESEARCH
5.11
IMPACT OF 2025 US TARIFF ON EPIGENETICS MARKET
5.11.3
PRICE IMPACT ANALYSIS
5.11.4
IMPACT ON COUNTRIES/REGIONS
5.11.5
IMPACT ON END-USE INDUSTRIES
5.11.5.1
PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
5.11.5.2
CONTRACT RESEARCH ORGANIZATIONS
5.11.5.3
ACADEMIC AND RESEARCH INSTITUTES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
AI-driven epigenomics revolutionizes market potential with cutting-edge patents and transformative applications.92
6.1.1.1
DNA METHYLATION CONVERSION TECHNOLOGIES
6.1.1.2
CHROMATIN IMMUNOPRECIPITATION/CHIP
6.1.1.3
ATAC-BASED CHROMATIN ACCESSIBILITY PROFILING
6.1.2
COMPLEMENTARY TECHNOLOGIES
6.1.2.1
SINGLE-CELL PARTITIONING AND EPIGENOMIC BARCODING
6.1.2.2
AI/ML-BASED EPIGENOMIC INTERPRETATION
6.1.3
ADJACENT TECHNOLOGIES
6.1.3.1
CRISPR-BASED EPIGENOME MODULATION
6.1.3.2
SPATIAL EPIGENOMICS
6.3.2
NUMBER OF PATENTS FILED, BY DOCUMENT TYPE
6.3.3
LIST OF KEY PATENTS
6.5
IMPACT OF AI/GEN AI ON EPIGENETICS MARKET
6.5.1
TOP USE CASES AND MARKET POTENTIAL
6.5.2
BEST PRACTICES IN AI-ENABLED EPIGENETICS WORKFLOWS
6.5.3
CASE STUDIES OF AI IMPLEMENTATION IN EPIGENETICS MARKET
6.5.4
INTERCONNECTED ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.5.5
CLIENTS’ READINESS TO ADOPT AI-INTEGRATED EPIGENETICS TECHNOLOGIES
7
REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
Discover how global regulations drive sustainability through compliance and eco-standards.103
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2.4
REST OF THE WORLD
7.2
SUSTAINABILITY INITIATIVES
7.3
IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
7.4
CERTIFICATIONS, LABELING, & ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Understand stakeholder influence and unmet needs to optimize your customer engagement strategy.113
8.1
DECISION-MAKING PROCESS
8.2
KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
8.2.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2
KEY BUYING CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
EPIGENETICS MARKET, BY OFFERING
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 15 Data Tables117
9.2.1
RISING ADOPTION OF WORKFLOW-READY EPIGENETICS PRODUCTS TO PROPEL MARKET
9.3.1
RISING OUTSOURCING OF COMPLEX EPIGENOMIC WORKFLOWS TO DRIVE MARKET
10
EPIGENETICS MARKET, BY PRODUCT
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 129 Data Tables125
10.2.1.1
GROWING DEMAND FOR RECOMBINANT ANTIBODIES FOR DETECTION OF EPIGENETIC TARGETS TO PROPEL MARKET
10.2.2
ISOLATION/EXTRACTION KITS & REAGENTS
10.2.2.1
RISING NEED FOR HIGH-QUALITY, AUTOMATION-READY SAMPLE PREPARATION TO PROPEL MARKET
10.2.3
CHIP-SEQUENCING KITS & REAGENTS
10.2.3.1
VERSATILE APPLICATIONS OF CHROMATIN IMMUNOPRECIPITATION PERTAINING TO EPIGENETIC REGULATORY SYSTEMS TO BOOST MARKET
10.2.4
BISULFITE CONVERSION KITS & REAGENTS
10.2.4.1
EFFECTIVE OUTCOMES ASSOCIATED WITH BISULFITE CONVERSION TO SUSTAIN GROWTH
10.2.5
WHOLE-GENOME AMPLIFICATION KITS & REAGENTS
10.2.5.1
RISING USE OF LOW-INPUT AND SINGLE-CELL EPIGENOMIC WORKFLOWS TO STIMULATE GROWTH
10.2.6
CUT&RUN/CUT&TAG KITS & REAGENTS
10.2.6.1
RISING ADOPTION OF LOW-INPUT CHROMATIN PROFILING WORKFLOWS TO STIMULATE GROWTH
10.2.7
5-HMC & 5-MC ANALYSIS KITS & REAGENTS
10.2.7.1
INTRODUCTION OF UNIQUE KITS FOR 5-MC AND 5-HMC ANALYSIS TO SUPPORT GROWTH
10.2.8.1
RISING IMPORTANCE OF CHROMATIN-ASSOCIATED PROTEINS AND HISTONES IN EPIGENETIC RESEARCH TO PROPEL GROWTH
10.2.9
OTHER KITS & REAGENTS
10.3.1.1
RISING NEED FOR URACIL-TOLERANT, LOW-BIAS DNA AMPLIFICATION TO FACILITATE GROWTH
10.3.2.1
RISING NEED FOR EFFICIENT ADAPTER LIGATION IN LOW-INPUT EPIGENOMIC LIBRARY PREPARATION TO SPUR GROWTH
10.3.3.1
RISING ADOPTION OF TAGMENTATION-BASED CHROMATIN PROFILING TO FACILITATE GROWTH
10.3.4
CONVERSION ENZYMES
10.3.4.1
RISING SHIFT TOWARD ENZYMATIC DNA CONVERSION FOR LOW-DAMAGE METHYLOME PROFILING TO SPUR GROWTH
10.3.5
PROTEIN-MODIFYING ENZYMES
10.3.5.1
RISING FOCUS ON HISTONE POST-TRANSLATIONAL MODIFICATION ANALYSIS TO SPUR GROWTH
10.4
INSTRUMENTS & ACCESSORIES
10.4.1
RISING ADOPTION OF HIGH-THROUGHPUT, AUTOMATED, AND LONG-READ EPIGENOMIC PLATFORMS TO EXPEDITE GROWTH
11
EPIGENETICS MARKET, BY SERVICE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 43 Data Tables190
11.2
DNA METHYLATION PROFILING SERVICES
11.2.1
OUTSOURCING OF COMPLEX METHYLATION WORKFLOWS AND ONCOLOGY BIOMARKER RESEARCH TO DRIVE MARKET
11.3
CHROMATIN PROFILING SERVICES
11.3.1
RISING OUTSOURCING OF LOW-INPUT AND MULTI-OMIC CHROMATIN MAPPING WORKFLOWS TO DRIVE MARKET
11.4
CHROMATIN ACCESSIBILITY PROFILING SERVICES
11.4.1
RISING USE OF SINGLE-CELL EPIGENOMIC PROFILING IN EMBRYO AND LINEAGE-DEVELOPMENT RESEARCH TO PROPEL MARKET
11.5
SINGLE-CELL EPIGENOMICS SERVICES
11.5.1
RISING NEED FOR CELL-LEVEL REGULATORY INSIGHTS TO AID GROWTH
11.6
MULTI-OMICS SERVICES
11.6.1
RISING DEMAND FOR INTEGRATED EPIGENOMIC, GENOMIC, AND TRANSCRIPTOMIC INTERPRETATION TO SUPPORT GROWTH
12
EPIGENETICS MARKET, BY TECHNOLOGY
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 36 Data Tables213
12.2
NEXT-GENERATION SEQUENCING
12.2.1
INCREASING LAUNCHES OF NGS PLATFORMS TO DRIVE GROWTH
12.3.1
RISING NUMBER OF PCR-BASED EPIGENETICS SERVICE PROVIDERS TO DRIVE MARKET
12.4.1
GROWING DEMAND FOR MASS SPECTROMETRY IN COMPREHENSIVE STUDIES ON HISTONE EPIGENETICS TO BOOST MARKET
12.5.1
RISING USE OF SONICATION IN SCIENTIFIC AND INDUSTRIAL SETTINGS TO DRIVE MARKET
13
EPIGENETICS MARKET, BY METHOD
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 23 Data Tables233
13.2.1
RISING USE OF METHYLATION-BASED BIOMARKERS IN ONCOLOGY, LIQUID BIOPSY, AND PRECISION MEDICINE TO SPUR GROWTH
13.3
HISTONE MODIFICATION
13.3.1
EXPANDING USE OF HISTONE MODIFICATION PROFILING IN CHROMATIN BIOLOGY, DRUG DISCOVERY, AND MULTI-OMICS RESEARCH TO DRIVE MARKET
14
EPIGENETICS MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 51 Data Tables245
14.2.1
RISING USE OF EPIGENETIC BIOMARKERS AND CHROMATIN-REGULATING DRUG TARGETS TO BOOST MARKET
14.3.1
INCREASING USE OF DNA METHYLATION BIOMARKERS TO ADVANCE METABOLIC DISEASE RISK PREDICTION AND THERAPEUTIC RESEARCH
14.4.1
RISING USE OF EPIGENETIC IMMUNE PROFILING TO DRIVE MARKET
14.5
DEVELOPMENTAL BIOLOGY
14.5.1
INCREASED USE OF SINGLE-CELL EPIGENOMIC PROFILING IN EMBRYO AND LINEAGE-DEVELOPMENT RESEARCH TO PROPEL MARKET
14.6
CARDIOVASCULAR DISEASES
14.6.1
RISING USE OF DNA METHYLATION BIOMARKERS FOR CARDIOVASCULAR RISK PREDICTION AND THERAPEUTIC TARGET DISCOVERY TO AID GROWTH
14.7
POPULATION SCREENING
14.7.1
INCREASING USE OF DNA METHYLATION BIOMARKERS FOR EXPOSURE-LINKED POPULATION RISK ASSESSMENT TO AID GROWTH
15
EPIGENETIC PRODUCTS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 29 Data Tables273
15.2
ACADEMIC & RESEARCH INSTITUTES
15.2.1
INCREASED IN-HOUSE ADOPTION OF ADVANCED EPIGENOMICS PRODUCTS ACROSS ACADEMIC DISCOVERY RESEARCH TO FAVOR GROWTH
15.3
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
15.3.1
RISING USE OF EPIGENETICS PRODUCTS IN DRUG DISCOVERY TO PROPEL MARKET
15.4.1
RISING INTEGRATION OF METHYLATION-BASED MOLECULAR PROFILING IN HOSPITAL ONCOLOGY WORKFLOWS TO PROPEL MARKET
15.5
CONTRACT RESEARCH ORGANIZATIONS
15.5.1
INCREASING DEMAND FOR STANDARDIZED AND SCALABLE EPIGENOMIC WORKFLOWS TO DRIVE MARKET
16
EPIGENETICS SERVICES MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 22 Data Tables289
16.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
16.2.1
RISING USE OF OUTSOURCED EPIGENETIC BIOMARKER AND TARGET-VALIDATION SERVICES TO ACCELERATE DRUG DEVELOPMENT DECISIONS
16.3
ACADEMIC & RESEARCH INSTITUTES
16.3.1
INCREASING VOLUME OF HIGH-THROUGHPUT EPIGENOMIC DATA TO AUGMENT GROWTH
16.4.1
RISING USE OF OUTSOURCED METHYLATION PROFILING AND CLASSIFIER-BASED INTERPRETATION TO AID GROWTH
17
EPIGENETICS MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 16 Countries | 287 Data Tables.301
17.2.1.1
STRONG PHARMACEUTICAL R&D INTENSITY AND ADVANCED GENOMICS INFRASTRUCTURE TO DRIVE MARKET
17.2.2.1
PRESENCE OF ADVANCED CLINICAL GENOMICS INFRASTRUCTURE TO SUPPORT MARKET GROWTH
17.3.1.1
ESTABLISHED LIFE SCIENCES SUPPLY ECOSYSTEM TO DRIVE MARKET
17.3.2.1
GROWING EMPHASIS ON PRECISION MEDICINE TO PROPEL MARKET
17.3.3.1
STRONG ONCOLOGY RESEARCH ECOSYSTEM TO SUPPORT MARKET GROWTH
17.3.4.1
HIGH INCIDENCE OF CANCER TO DRIVE MARKET
17.3.5.1
WELL-ESTABLISHED NETWORK OF RESEARCH CENTERS AND UNIVERSITIES TO PROPEL MARKET
17.4.1.1
ADVANCED METHYLATION DETECTION AND SEQUENCING SERVICE CAPACITY TO ACCELERATE GROWTH
17.4.2.1
INCREASING COLLABORATIONS BETWEEN RESEARCH & ACADEMIC ORGANIZATIONS TO FAVOR GROWTH
17.4.3.1
EXPANDING GENOMICS INFRASTRUCTURE TO DRIVE MARKET
17.4.4.1
STRONG GENOMICS INFRASTRUCTURE TO PROPEL MARKET
17.4.5.1
METHYLATION PROFILING AND AI-ENABLED EPIGENOMIC ANALYSIS TO FOSTER GROWTH
17.4.6
REST OF ASIA PACIFIC
17.5.1.1
RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET
17.5.2.1
GROWING ADOPTION OF CUTTING-EDGE TECHNOLOGIES TO DRIVE MARKET
17.5.3
REST OF LATIN AMERICA
17.6.1.1.1
GROWING HEALTHCARE EXPENDITURE TO PROPEL MARKET
17.6.1.2.1
NATIONAL GENOMICS PROGRAMS AND METHYLATION-ENABLED SEQUENCING TO SPUR GROWTH
17.6.1.3
REST OF GCC COUNTRIES
17.6.2
REST OF MIDDLE EAST
17.7.1
POPULATION-SPECIFIC BIOMARKER DISCOVERY AND DISEASE-FOCUSED METHYLATION RESEARCH TO AUGMENT GROWTH
18
COMPETITIVE LANDSCAPE
Uncover strategic insights and market positioning of key players and startups through 2025.435
18.2
KEY PLAYER STRATEGIES/RIGHT TO WIN, JANUARY 2023–MAY 2026
18.4
MARKET SHARE ANALYSIS, 2025
18.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
18.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2025
18.5.5.1
COMPANY FOOTPRINT
18.5.5.2
REGION FOOTPRINT
18.5.5.3
PRODUCT FOOTPRINT
18.5.5.4
SERVICE FOOTPRINT
18.5.5.5
METHOD FOOTPRINT
18.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
18.6.1
PROGRESSIVE COMPANIES
18.6.2
RESPONSIVE COMPANIES
18.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
18.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
18.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
18.7
COMPANY VALUATION AND FINANCIAL METRICS
18.9
COMPETITIVE SCENARIO
18.9.1
PRODUCT/SERVICE LAUNCHES
19
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)456
19.1.1
THERMO FISHER SCIENTIFIC INC.
19.1.1.1
BUSINESS OVERVIEW
19.1.1.2
PRODUCTS/SERVICES OFFERED
19.1.1.3
RECENT DEVELOPMENTS
19.1.1.3.1
PRODUCT LAUNCHES
19.1.1.4.2
STRATEGIC CHOICES
19.1.1.4.3
WEAKNESSES AND COMPETITIVE THREATS
19.1.4
DANAHER CORPORATION
19.1.5
BIO-RAD LABORATORIES, INC.
19.1.8
ACTIVE MOTIF, INC.
19.1.9
NEW ENGLAND BIOLABS
19.1.11
ZYMO RESEARCH CORPORATION
19.1.12
HOLOGIC DIAGENODE
19.1.13
F. HOFFMANN-LA ROCHE LTD.
19.1.14
PROMEGA CORPORATION
19.1.15
EPIGENTEK GROUP INC.
19.2.5
BPS BIOSCIENCE, INC.
19.2.6
ABNOVA CORPORATION
19.2.7
CREATIVE DIAGNOSTICS
19.2.10
NOVOGENE CO., LTD.
20
RESEARCH METHODOLOGY
529
20.1.1.1
KEY DATA FROM SECONDARY SOURCES
20.1.2.1
KEY DATA FROM PRIMARY SOURCES
20.1.2.2
KEY PRIMARY PARTICIPANTS
20.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
20.1.2.4
KEY INDUSTRY INSIGHTS
20.2
MARKET SIZE ESTIMATION
20.2.1
GLOBAL EPIGENETICS MARKET ESTIMATION, 2025
20.2.2
SEGMENTAL MARKET SIZE ESTIMATION
20.3
MARKET GROWTH RATE PROJECTIONS
20.6
RESEARCH ASSUMPTIONS
20.7
RESEARCH LIMITATIONS AND RISK ASSESSMENT
21.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
21.3
CUSTOMIZATION OPTIONS
TABLE 1
EPIGENETICS MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2
EPIGENETICS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 3
EPIGENETICS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 4
EPIGENETICS MARKET: ROLE OF PLAYERS IN ECOSYSTEM
TABLE 5
AVERAGE SELLING PRICE TREND OF EPIGENETIC INSTRUMENTS, 2023–2025
TABLE 6
AVERAGE SELLING PRICE TREND OF EPIGENETIC KITS & REAGENTS, 2023–2025 (USD)
TABLE 7
AVERAGE SELLING PRICE TREND OF EPIGENETIC INSTRUMENTS, BY REGION, 2023–2025 (USD)
TABLE 8
AVERAGE SELLING PRICE TREND OF EPIGENETIC KITS & REAGENTS, BY REGION, 2023–2025 (USD)
TABLE 9
IMPORT DATA FOR HS CODE 9027.50-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 10
EXPORT DATA FOR HS CODE 9027.50-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 11
IMPORT DATA FOR HS CODE 3822.00-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 12
EXPORT DATA FOR HS CODE 3822.00-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 13
EPIGENETICS MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2026–JUNE 2027
TABLE 14
RECIPROCAL TARIFF RATES ADJUSTED BY US
TABLE 15
CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES
TABLE 16
NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2015–2025
TABLE 17
LIST OF KEY PATENTS IN EPIGENETICS MARKET, 2023–2025
TABLE 18
CASE STUDIES OF AI IMPLEMENTATION IN EPIGENETICS MARKET
TABLE 19
CLIENTS’ READINESS TO ADOPT AI-INTEGRATED EPIGENETICS TECHNOLOGIES
TABLE 20
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24
MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25
AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 26
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
TABLE 27
KEY BUYING CRITERIA, BY END USER
TABLE 28
EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 29
EPIGENETIC PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 30
NORTH AMERICA: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 31
EUROPE: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 32
ASIA PACIFIC: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 33
LATIN AMERICA: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 34
MIDDLE EAST: EPIGENETIC PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 35
GCC COUNTRIES: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36
EPIGENETIC SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 37
NORTH AMERICA: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38
EUROPE: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 39
ASIA PACIFIC: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40
LATIN AMERICA: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 41
MIDDLE EAST: EPIGENETIC SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 42
GCC COUNTRIES: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43
EPIGENETICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 44
EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 45
EPIGENETICS MARKET FOR KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 46
NORTH AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47
EUROPE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 48
ASIA PACIFIC: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49
LATIN AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50
MIDDLE EAST: EPIGENETICS MARKET FOR KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 51
GCC COUNTRIES: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52
EPIGENETICS MARKET FOR ANTIBODIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 53
NORTH AMERICA: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54
EUROPE: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 55
ASIA PACIFIC: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56
LATIN AMERICA: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57
MIDDLE EAST: EPIGENETICS MARKET FOR ANTIBODIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 58
GCC COUNTRIES: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59
EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 60
NORTH AMERICA: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 61
EUROPE: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62
ASIA PACIFIC: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63
LATIN AMERICA: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 64
MIDDLE EAST: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 65
GCC COUNTRIES: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66
EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 67
NORTH AMERICA: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68
EUROPE: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 69
ASIA PACIFIC: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70
LATIN AMERICA: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 71
MIDDLE EAST: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 72
GCC COUNTRIES: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73
EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 74
NORTH AMERICA: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75
EUROPE: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 76
ASIA PACIFIC: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77
LATIN AMERICA: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 78
MIDDLE EAST: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 79
GCC COUNTRIES: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80
EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 81
NORTH AMERICA: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82
EUROPE: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83
ASIA PACIFIC: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84
LATIN AMERICA: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 85
MIDDLE EAST: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 86
GCC COUNTRIES: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87
EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 88
NORTH AMERICA: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89
EUROPE: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 90
ASIA PACIFIC: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 91
LATIN AMERICA: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92
MIDDLE EAST: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 93
GCC COUNTRIES: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94
EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 95
NORTH AMERICA: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96
EUROPE: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97
ASIA PACIFIC: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98
LATIN AMERICA: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 99
MIDDLE EAST: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 100
GCC COUNTRIES: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 101
EPIGENETICS MARKET FOR HISTONES, BY REGION, 2024–2031 (USD MILLION)
TABLE 102
NORTH AMERICA: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103
EUROPE: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104
ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 105
LATIN AMERICA: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 106
MIDDLE EAST: EPIGENETICS MARKET FOR HISTONES, BY REGION, 2024–2031 (USD MILLION)
TABLE 107
GCC COUNTRIES: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108
EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 109
NORTH AMERICA: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 110
EUROPE: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111
ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 112
LATIN AMERICA: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113
MIDDLE EAST: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 114
GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 115
EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 116
EPIGENETICS MARKET FOR ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 117
NORTH AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118
EUROPE: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119
ASIA PACIFIC: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 120
LATIN AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 121
MIDDLE EAST: EPIGENETICS MARKET FOR ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 122
GCC COUNTRIES: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123
EPIGENETICS MARKET FOR DNA POLYMERASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 124
NORTH AMERICA: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125
EUROPE: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 126
ASIA PACIFIC: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 127
LATIN AMERICA: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 128
MIDDLE EAST: EPIGENETICS MARKET FOR DNA POLYMERASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 129
GCC COUNTRIES: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130
EPIGENETICS MARKET FOR DNA LIGASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 131
NORTH AMERICA: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132
EUROPE: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 133
ASIA PACIFIC: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 134
LATIN AMERICA: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135
MIDDLE EAST: EPIGENETICS MARKET FOR DNA LIGASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 136
GCC COUNTRIES: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137
EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY REGION, 2024–2031 (USD MILLION)
TABLE 138
NORTH AMERICA: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 139
EUROPE: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 140
ASIA PACIFIC: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141
LATIN AMERICA: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 142
MIDDLE EAST: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY REGION, 2024–2031 (USD MILLION)
TABLE 143
GCC COUNTRIES: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 144
EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 145
NORTH AMERICA: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146
EUROPE: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 147
ASIA PACIFIC: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148
LATIN AMERICA: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 149
MIDDLE EAST: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 150
GCC COUNTRIES: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 151
EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 152
NORTH AMERICA: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153
EUROPE: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 154
ASIA PACIFIC: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155
LATIN AMERICA: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 156
MIDDLE EAST: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 157
GCC COUNTRIES: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 158
EPIGENETICS MARKET FOR OTHER ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 159
NORTH AMERICA: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 160
EUROPE: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 161
ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162
LATIN AMERICA: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 163
MIDDLE EAST: EPIGENETICS MARKET FOR OTHER ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 164
GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165
EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 166
NORTH AMERICA: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167
EUROPE: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 168
ASIA PACIFIC: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169
LATIN AMERICA: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170
MIDDLE EAST: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 171
GCC COUNTRIES: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172
EPIGENETICS MARKET, BY SERVICE, 2024–2031 (USD MILLION)
TABLE 173
EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 174
NORTH AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175
EUROPE: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176
ASIA PACIFIC: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177
LATIN AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 178
MIDDLE EAST: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 179
GCC COUNTRIES: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 180
EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 181
NORTH AMERICA: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182
EUROPE: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 183
ASIA PACIFIC: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184
LATIN AMERICA: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 185
MIDDLE EAST: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 186
GCC COUNTRIES: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 187
EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 188
NORTH AMERICA: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189
EUROPE: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190
ASIA PACIFIC: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 191
LATIN AMERICA: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 192
MIDDLE EAST: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 193
GCC COUNTRIES: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194
EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 195
NORTH AMERICA: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 196
EUROPE: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 197
ASIA PACIFIC: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 198
LATIN AMERICA: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 199
MIDDLE EAST: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 200
GCC COUNTRIES: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 201
EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 202
NORTH AMERICA: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 203
EUROPE: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204
ASIA PACIFIC: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 205
LATIN AMERICA: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206
MIDDLE EAST: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 207
GCC COUNTRIES: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 208
EPIGENETICS MARKET FOR OTHER SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 209
NORTH AMERICA: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 210
EUROPE: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211
ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 212
LATIN AMERICA: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 213
MIDDLE EAST: EPIGENETICS MARKET FOR OTHER SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 214
GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 215
EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 216
EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2024–2031 (USD MILLION)
TABLE 217
NORTH AMERICA: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 218
EUROPE: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 219
ASIA PACIFIC: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 220
LATIN AMERICA: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 221
MIDDLE EAST: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2024–2031 (USD MILLION)
TABLE 222
GCC COUNTRIES: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 223
EPIGENETICS MARKET FOR PCR & QPCR, BY REGION, 2024–2031 (USD MILLION)
TABLE 224
NORTH AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 225
EUROPE: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 226
ASIA PACIFIC: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 227
LATIN AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 228
MIDDLE EAST: EPIGENETICS MARKET FOR PCR & QPCR, BY REGION, 2024–2031 (USD MILLION)
TABLE 229
GCC COUNTRIES: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 230
EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2024–2031 (USD MILLION)
TABLE 231
NORTH AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 232
EUROPE: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 233
ASIA PACIFIC: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 234
LATIN AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 235
MIDDLE EAST: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2024–2031 (USD MILLION)
TABLE 236
GCC COUNTRIES: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 237
EPIGENETICS MARKET FOR SONICATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 238
NORTH AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 239
EUROPE: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 240
ASIA PACIFIC: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 241
LATIN AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 242
MIDDLE EAST: EPIGENETICS MARKET FOR SONICATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 243
GCC COUNTRIES: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 244
EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 245
NORTH AMERICA: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 246
EUROPE: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 247
ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 248
LATIN AMERICA: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 249
MIDDLE EAST: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 250
GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 251
EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 252
EPIGENETICS MARKET FOR DNA METHYLATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 253
NORTH AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 254
EUROPE: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 255
ASIA PACIFIC: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 256
LATIN AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 257
MIDDLE EAST: EPIGENETICS MARKET FOR DNA METHYLATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 258
GCC COUNTRIES: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 259
COMMON HISTONE MODIFICATIONS AND RESPECTIVE LOCATIONS
TABLE 260
EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 261
NORTH AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 262
EUROPE: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 263
ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 264
LATIN AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 265
MIDDLE EAST: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 266
GCC COUNTRIES: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 267
EPIGENETICS MARKET FOR OTHER METHODS, BY REGION, 2024–2031 (USD MILLION)
TABLE 268
NORTH AMERICA: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 269
EUROPE: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 270
ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 271
LATIN AMERICA: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 272
MIDDLE EAST: EPIGENETICS MARKET FOR OTHER METHODS, BY REGION, 2024–2031 (USD MILLION)
TABLE 273
GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 274
EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 275
EPIGENOME-TARGETING CANCER DRUGS APPROVED OR IN CLINICAL TRIALS
TABLE 276
EPIGENETICS MARKET FOR ONCOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 277
NORTH AMERICA: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 278
EUROPE: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 279
ASIA PACIFIC: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 280
LATIN AMERICA: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 281
MIDDLE EAST: EPIGENETICS MARKET FOR ONCOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 282
GCC COUNTRIES: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 283
EPIGENETICS MARKET FOR METABOLIC DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 284
NORTH AMERICA: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 285
EUROPE: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 286
ASIA PACIFIC: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 287
LATIN AMERICA: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 288
MIDDLE EAST: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 289
GCC COUNTRIES: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 290
EPIGENETICS MARKET FOR IMMUNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 291
NORTH AMERICA: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 292
EUROPE: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 293
ASIA PACIFIC: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 294
LATIN AMERICA: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 295
MIDDLE EAST: EPIGENETICS MARKET FOR IMMUNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 296
GCC COUNTRIES: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 297
EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 298
NORTH AMERICA: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 299
EUROPE: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 300
ASIA PACIFIC: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 301
LATIN AMERICA: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 302
MIDDLE EAST: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 303
GCC COUNTRIES: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 304
EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 305
NORTH AMERICA: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 306
EUROPE: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 307
ASIA PACIFIC: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 308
LATIN AMERICA: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 309
MIDDLE EAST: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 310
GCC COUNTRIES: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 311
EPIGENETICS MARKET FOR POPULATION SCREENING, BY REGION, 2024–2031 (USD MILLION)
TABLE 312
NORTH AMERICA: EPIGENETICS MARKET FOR POPULATION SCREENING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 313
EUROPE: EPIGENETICS MARKET FOR POPULATION SCREENING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 314
ASIA PACIFIC: EPIGENETICS MARKET FOR POPULATION SCREENING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 315
LATIN AMERICA: EPIGENETICS MARKET FOR POPULATION SCREENING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 316
MIDDLE EAST: EPIGENETICS MARKET FOR POPULATION SCREENING, BY REGION, 2024–2031 (USD MILLION)
TABLE 317
GCC COUNTRIES: EPIGENETICS MARKET FOR POPULATION SCREENING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 318
EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 319
NORTH AMERICA: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 320
EUROPE: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 321
ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 322
LATIN AMERICA: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 323
MIDDLE EAST: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 324
GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 325
EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 326
EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 327
NORTH AMERICA: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 328
EUROPE: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 329
ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 330
LATIN AMERICA: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 331
MIDDLE EAST: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 332
GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 333
EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 334
NORTH AMERICA: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 335
EUROPE: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 336
ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 337
LATIN AMERICA: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 338
MIDDLE EAST: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 339
GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 340
EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 341
NORTH AMERICA: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 342
EUROPE: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 343
ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 344
LATIN AMERICA: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 345
MIDDLE EAST: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 346
GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 347
EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 348
NORTH AMERICA: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 349
EUROPE: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 350
ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 351
LATIN AMERICA: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 352
MIDDLE EAST: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 353
GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 354
EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 355
EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 356
NORTH AMERICA: EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 357
EUROPE: EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 358
ASIA PACIFIC: EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 359
LATIN AMERICA: EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 360
MIDDLE EAST: EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 361
GCC COUNTRIES: EPIGENETICS SERVICE MARKET PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 362
EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 363
NORTH AMERICA: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 364
EUROPE: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 365
ASIA PACIFIC: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 366
LATIN AMERICA: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 367
MIDDLE EAST: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 368
GCC COUNTRIES: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 369
EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 370
NORTH AMERICA: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 371
EUROPE: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 372
ASIA PACIFIC: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 373
LATIN AMERICA: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 374
MIDDLE EAST: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 375
GCC COUNTRIES: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 376
EPIGENETICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 377
NORTH AMERICA: EPIGENETICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 378
NORTH AMERICA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 379
NORTH AMERICA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 380
NORTH AMERICA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 381
NORTH AMERICA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 382
NORTH AMERICA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 383
NORTH AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 384
NORTH AMERICA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 385
NORTH AMERICA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 386
NORTH AMERICA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 387
NORTH AMERICA: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 388
US: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 389
US: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 390
US: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 391
US: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 392
US: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 393
US: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 394
US: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 395
US: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 396
US: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 397
US: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 398
CANADA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 399
CANADA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 400
CANADA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 401
CANADA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 402
CANADA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 403
CANADA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 404
CANADA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 405
CANADA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 406
CANADA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 407
CANADA: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 408
EUROPE: EPIGENETICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 409
EUROPE: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 410
EUROPE: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 411
EUROPE: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 412
EUROPE: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 413
EUROPE: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 414
EUROPE: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 415
EUROPE: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 416
EUROPE: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 417
EUROPE: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 418
EUROPE: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 419
GERMANY: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 420
GERMANY: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 421
GERMANY: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 422
GERMANY: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 423
GERMANY: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 424
GERMANY: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 425
GERMANY: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 426
GERMANY: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 427
GERMANY: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 428
GERMANY: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 429
UK: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 430
UK: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 431
UK: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 432
UK: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 433
UK: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 434
UK: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 435
UK: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 436
UK: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 437
UK: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 438
UK: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 439
FRANCE: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 440
FRANCE: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 441
FRANCE: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 442
FRANCE: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 443
FRANCE: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 444
FRANCE: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 445
FRANCE: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 446
FRANCE: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 447
FRANCE: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 448
FRANCE: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 449
ITALY: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 450
ITALY: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 451
ITALY: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 452
ITALY: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 453
ITALY: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 454
ITALY: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 455
ITALY: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 456
ITALY: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 457
ITALY: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 458
ITALY: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 459
SPAIN: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 460
SPAIN: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 461
SPAIN: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 462
SPAIN: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 463
SPAIN: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 464
SPAIN: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 465
SPAIN: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 466
SPAIN: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 467
SPAIN: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 468
SPAIN: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 469
REST OF EUROPE: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 470
REST OF EUROPE: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 471
REST OF EUROPE: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 472
REST OF EUROPE: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 473
REST OF EUROPE: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 474
REST OF EUROPE: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 475
REST OF EUROPE: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 476
REST OF EUROPE: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 477
REST OF EUROPE: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 478
REST OF EUROPE: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 479
ASIA PACIFIC: EPIGENETICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 480
ASIA PACIFIC: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 481
ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 482
ASIA PACIFIC: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 483
ASIA PACIFIC: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 484
ASIA PACIFIC: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 485
ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 486
ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 487
ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 488
ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 489
ASIA PACIFIC: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 490
CHINA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 491
CHINA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 492
CHINA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 493
CHINA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 494
CHINA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 495
CHINA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 496
CHINA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 497
CHINA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 498
CHINA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 499
CHINA: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 500
JAPAN: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 501
JAPAN: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 502
JAPAN: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 503
JAPAN: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 504
JAPAN: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 505
JAPAN: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 506
JAPAN: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 507
JAPAN: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 508
JAPAN: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 509
JAPAN: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 510
INDIA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 511
INDIA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 512
INDIA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 513
INDIA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 514
INDIA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 515
INDIA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 516
INDIA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 517
INDIA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 518
INDIA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 519
INDIA: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 520
AUSTRALIA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 521
AUSTRALIA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 522
AUSTRALIA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 523
AUSTRALIA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 524
AUSTRALIA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 525
AUSTRALIA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 526
AUSTRALIA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 527
AUSTRALIA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 528
AUSTRALIA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 529
AUSTRALIA: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 530
SOUTH KOREA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 531
SOUTH KOREA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 532
SOUTH KOREA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 533
SOUTH KOREA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 534
SOUTH KOREA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 535
SOUTH KOREA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 536
SOUTH KOREA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 537
SOUTH KOREA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 538
SOUTH KOREA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 539
SOUTH KOREA: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 540
REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 541
REST OF ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 542
REST OF ASIA PACIFIC: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 543
REST OF ASIA PACIFIC: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 544
REST OF ASIA PACIFIC: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 545
REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 546
REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 547
REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 548
REST OF ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 549
REST OF ASIA PACIFIC: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 550
LATIN AMERICA: EPIGENETICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 551
LATIN AMERICA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 552
LATIN AMERICA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 553
LATIN AMERICA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 554
LATIN AMERICA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 555
LATIN AMERICA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 556
LATIN AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 557
LATIN AMERICA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 558
LATIN AMERICA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 559
LATIN AMERICA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 560
LATIN AMERICA: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 561
BRAZIL: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 562
BRAZIL: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 563
BRAZIL: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 564
BRAZIL: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 565
BRAZIL: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 566
BRAZIL: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 567
BRAZIL: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 568
BRAZIL: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 569
BRAZIL: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 570
BRAZIL: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 571
MEXICO: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 572
MEXICO: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 573
MEXICO: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 574
MEXICO: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 575
MEXICO: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 576
MEXICO: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 577
MEXICO: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 578
MEXICO: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 579
MEXICO: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 580
MEXICO: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 581
REST OF LATIN AMERICA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 582
REST OF LATIN AMERICA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 583
REST OF LATIN AMERICA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 584
REST OF LATIN AMERICA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 585
REST OF LATIN AMERICA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 586
REST OF LATIN AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 587
REST OF LATIN AMERICA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 588
REST OF LATIN AMERICA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 589
REST OF LATIN AMERICA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 590
REST OF LATIN AMERICA: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 591
MIDDLE EAST: EPIGENETICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 592
MIDDLE EAST: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 593
MIDDLE EAST: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 594
MIDDLE EAST: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 595
MIDDLE EAST: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 596
MIDDLE EAST: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 597
MIDDLE EAST: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 598
MIDDLE EAST: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 599
MIDDLE EAST: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 600
MIDDLE EAST: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 601
MIDDLE EAST: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 602
GCC COUNTRIES: EPIGENETICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 603
GCC COUNTRIES: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 604
GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 605
GCC COUNTRIES: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 606
GCC COUNTRIES: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 607
GCC COUNTRIES: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 608
GCC COUNTRIES: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 609
GCC COUNTRIES: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 610
GCC COUNTRIES: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 611
GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 612
GCC COUNTRIES: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 613
SAUDI ARABIA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 614
SAUDI ARABIA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 615
SAUDI ARABIA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 616
SAUDI ARABIA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 617
SAUDI ARABIA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 618
SAUDI ARABIA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 619
SAUDI ARABIA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 620
SAUDI ARABIA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 621
SAUDI ARABIA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 622
SAUDI ARABIA: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 623
UAE: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 624
UAE: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 625
UAE: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 626
UAE: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 627
UAE: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 628
UAE: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 629
UAE: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 630
UAE: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 631
UAE: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 632
UAE: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 633
REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 634
REST OF GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 635
REST OF GCC COUNTRIES: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 636
REST OF GCC COUNTRIES: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 637
REST OF GCC COUNTRIES: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 638
REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 639
REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 640
REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 641
REST OF GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 642
REST OF GCC COUNTRIES: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 643
REST OF MIDDLE EAST: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 644
REST OF MIDDLE EAST: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 645
REST OF MIDDLE EAST: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 646
REST OF MIDDLE EAST: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 647
REST OF MIDDLE EAST: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 648
REST OF MIDDLE EAST: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 649
REST OF MIDDLE EAST: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 650
REST OF MIDDLE EAST: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 651
EST OF MIDDLE EAST: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 652
REST OF MIDDLE EAST: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 653
AFRICA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 654
AFRICA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 655
AFRICA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 656
AFRICA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 657
AFRICA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 658
AFRICA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 659
AFRICA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 660
AFRICA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 661
AFRICA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 662
AFRICA: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 663
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN EPIGENETICS MARKET, JANUARY 2023–MAY 2026
TABLE 664
EPIGENETICS MARKET: DEGREE OF COMPETITION
TABLE 665
EPIGENETICS MARKET: REGION FOOTPRINT
TABLE 666
EPIGENETICS MARKET: PRODUCT FOOTPRINT
TABLE 667
EPIGENETICS MARKET: SERVICE FOOTPRINT
TABLE 668
EPIGENETICS MARKET: METHOD FOOTPRINT
TABLE 669
EPIGENETICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 670
EPIGENETICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 671
EPIGENETICS MARKET: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–MAY 2026
TABLE 672
EPIGENETICS MARKET: DEALS, JANUARY 2023–MAY 2026
TABLE 673
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 674
THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
TABLE 675
THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2023–MAY 2026
TABLE 676
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–MAY 2026
TABLE 677
ILLUMINA, INC.: COMPANY OVERVIEW
TABLE 678
ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED
TABLE 679
ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2023–MAY 2026
TABLE 680
ILLUMINA, INC.: DEALS, JANUARY 2023–MAY 2026
TABLE 681
MERCK KGAA: COMPANY OVERVIEW
TABLE 682
MERCK KGAA: PRODUCTS/SERVICES OFFERED
TABLE 683
DANAHER CORPORATION: COMPANY OVERVIEW
TABLE 684
DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 685
DANAHER CORPORATION: DEALS, JANUARY 2023–MAY 2026
TABLE 686
BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
TABLE 687
BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED
TABLE 688
REVVITY: COMPANY OVERVIEW
TABLE 689
REVVITY: PRODUCTS/SERVICES OFFERED
TABLE 690
PACBIO: COMPANY OVERVIEW
TABLE 691
PACBIO: PRODUCTS/SERVICES OFFERED
TABLE 692
PACBIO: PRODUCT LAUNCHES, JANUARY 2023–MAY 2026
TABLE 693
PACBIO: DEALS, JANUARY 2023–MAY 2026
TABLE 694
ACTIVE MOTIF, INC.: COMPANY OVERVIEW
TABLE 695
ACTIVE MOTIF, INC.: PRODUCTS/SERVICES OFFERED
TABLE 696
ACTIVE MOTIF, INC.: DEALS, JANUARY 2023–MAY 2026
TABLE 697
NEW ENGLAND BIOLABS: COMPANY OVERVIEW
TABLE 698
NEW ENGLAND BIOLABS: PRODUCTS/SERVICES OFFERED
TABLE 699
NEW ENGLAND BIOLABS: PRODUCT LAUNCHES, JANUARY 2023–MAY 2026
TABLE 700
NEW ENGLAND BIOLABS: DEALS, JANUARY 2023–MAY 2026
TABLE 701
QIAGEN: COMPANY OVERVIEW
TABLE 702
QIAGEN: PRODUCTS/SERVICES OFFERED
TABLE 703
QIAGEN: PRODUCT LAUNCHES, JANUARY 2023–MAY 2026
TABLE 704
ZYMO RESEARCH CORPORATION: COMPANY OVERVIEW
TABLE 705
ZYMO RESEARCH CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 706
ZYMO RESEARCH CORPORATION: PRODUCT LAUNCHES, JANUARY 2023–MAY 2026
TABLE 707
ZYMO RESEARCH CORPORATION: DEALS, JANUARY 2023–MAY 2026
TABLE 708
HOLOGIC DIAGENODE: COMPANY OVERVIEW
TABLE 709
HOLOGIC DIAGENODE: PRODUCTS/SERVICES OFFERED
TABLE 710
F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
TABLE 711
F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
TABLE 712
PROMEGA CORPORATION: COMPANY OVERVIEW
TABLE 713
PROMEGA CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 714
EPIGENTEK GROUP INC.: COMPANY OVERVIEW
TABLE 715
EPIGENTEK GROUP INC.: PRODUCTS/SERVICES OFFERED
TABLE 716
EPIGENTEK GROUP INC.: PRODUCT LAUNCHES, JANUARY 2023–MAY 2026
TABLE 717
EPICYPHER: COMPANY OVERVIEW
TABLE 718
FIOS GENOMICS: COMPANY OVERVIEW
TABLE 719
GENOMESCAN: COMPANY OVERVIEW
TABLE 720
CREATIVE BIOGENE: COMPANY OVERVIEW
TABLE 721
BPS BIOSCIENCE, INC.: COMPANY OVERVIEW
TABLE 722
ABNOVA CORPORATION: COMPANY OVERVIEW
TABLE 723
CREATIVE DIAGNOSTICS: COMPANY OVERVIEW
TABLE 724
BIOMODAL: COMPANY OVERVIEW
TABLE 725
10X GENOMICS: COMPANY OVERVIEW
TABLE 726
NOVOGENE CO., LTD.: COMPANY OVERVIEW
TABLE 727
IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
TABLE 728
RISK ASSESSMENT
FIGURE 1
EPIGENETICS MARKET SEGMENTATION
FIGURE 2
EPIGENETICS MARKET: REGIONAL SCOPE
FIGURE 3
EPIGENETICS MARKET: YEARS CONSIDERED
FIGURE 5
GLOBAL EPIGENETICS MARKET, 2024–2031
FIGURE 6
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN EPIGENETICS MARKET, 2023–2026
FIGURE 7
DISRUPTIONS INFLUENCING GROWTH OF EPIGENETICS MARKET
FIGURE 8
HIGH-GROWTH SEGMENTS IN EPIGENETICS MARKET, 2026–2031
FIGURE 9
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN EPIGENETICS MARKET DURING FORECAST PERIOD
FIGURE 10
GROWING EMPHASIS ON POPULATION SCREENING PROGRAMS TO DRIVE MARKET
FIGURE 11
DNA METHYLATION ACCOUNTED FOR LARGEST SHARE OF EPIGENETICS MARKET IN NORTH AMERICA IN 2025
FIGURE 12
ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
FIGURE 13
PRODUCTS TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 14
EPIGENETICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 15
EPIGENETICS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 16
EPIGENETICS MARKET: VALUE CHAIN ANALYSIS
FIGURE 17
EPIGENETICS MARKET: ECOSYSTEM ANALYSIS
FIGURE 18
EPIGENETICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 19
INVESTMENT AND FUNDING SCENARIO, 2023–2026
FIGURE 20
PATENT APPLICATIONS IN EPIGENETICS MARKET, JANUARY 2015–DECEMBER 2025
FIGURE 21
IMPACT OF AI/GEN AI ON EPIGENETICS MARKET
FIGURE 22
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
FIGURE 23
KEY BUYING CRITERIA, BY END USER
FIGURE 24
EPIGENETICS MARKET, BY PRODUCT, 2024–2031 (MILLION UNITS)
FIGURE 25
NORTH AMERICA: EPIGENETICS MARKET SNAPSHOT
FIGURE 26
ASIA PACIFIC: EPIGENETICS MARKET SNAPSHOT
FIGURE 27
REVENUE ANALYSIS OF KEY PLAYERS IN EPIGENETICS MARKET, 2021–2025
FIGURE 28
EPIGENETICS MARKET SHARE ANALYSIS, 2025
FIGURE 29
EPIGENETICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 30
EPIGENETICS MARKET: COMPANY FOOTPRINT
FIGURE 31
EPIGENETICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 32
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 33
EV/EBITDA OF KEY VENDORS
FIGURE 34
EPIGENETICS MARKET: BRAND COMPARATIVE ANALYSIS
FIGURE 35
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 36
ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
FIGURE 37
MERCK KGAA: COMPANY SNAPSHOT (2025)
FIGURE 38
DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 39
BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 40
REVVITY: COMPANY SNAPSHOT (2025)
FIGURE 41
PACBIO: COMPANY SNAPSHOT (2025)
FIGURE 42
QIAGEN: COMPANY SNAPSHOT (2025)
FIGURE 43
HOLOGIC DIAGENODE: COMPANY SNAPSHOT (2025)
FIGURE 44
F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025)
FIGURE 45
EPIGENETICS MARKET: RESEARCH DESIGN
FIGURE 46
EPIGENETICS MARKET: BREAKDOWN OF PRIMARIES
FIGURE 47
EPIGENETICS MARKET: INSIGHTS FROM PRIMARIES
FIGURE 48
GLOBAL EPIGENETICS MARKET ESTIMATION, 2025
FIGURE 49
EPIGENETICS MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH), 2025
FIGURE 50
ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE ANALYSIS (2025)
FIGURE 51
SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 52
EPIGENETICS MARKET: CAGR PROJECTIONS
FIGURE 53
EPIGENETICS MARKET: DATA TRIANGULATION
Methodology
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global epigenetics market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the epigenetics market. The secondary sources used for this study include World Health Organization (WHO), World Intellectual Property Organization (WIPO), International Union of Biochemistry and Molecular Biology (IUBMB), National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), Centers for Disease Control and Prevention (CDC), American Cancer Society (ACS), American Society for Biochemistry and Molecular Biology (ASBMB), Canadian Society for Molecular Biosciences (CSMB), National Institute of Environmental Health Sciences (NIEHS), Canadian Institutes of Health Research (CIHR), Genome Canada, and Central Drugs Standard Control Organisation (CDSCO). Academic Journals and Company Websites, corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations, among others. Secondary data were collected and analyzed to determine the overall size of the global epigenetics market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
Note: Tier 1 companies’ revenue is more than USD 10 billion; Tier 2 companies’ revenue ranges between USD 1 and 10 billion; and Tier 3 companies’ revenue ranges between USD 500 million and USD 1 billion
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the epigenetics market. These methods were also used extensively to estimate the size of various market segments.
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
The epigenetics market is defined as the use of products such as reagents & kits, instruments and software for isolation/extraction, target enrichment, amplification/library preparation, sequencing/profiling and bioinformatics & data analysis of epigenetic biomarkers and samples (biological samples such as liquid biopsy samples, tissue samples and nucleic acid & protein isolates). The report scope is inclusive of outsourcing services such as DNA methylation services, chromatin profiling services, and single-cell/multi-omics services, among others. These products & services applied in drug discovery & development (oncology, metabolic disorders, immunology, cardiovascular diseases), and research (developmental biology) are covered in the report scope.
Key Stakeholders
- Pharmaceutical & biotechnology companies
- Contract research organizations (CROs)
- Contract development and manufacturing organizations (CDMOs)
- Life science companies
- Academic & research institutes
- Private research institutes
- Venture capitalists & investors
- Market research & consulting firms
- Government associations
- Medical institutions & universities
- Hospitals & clinics
Report Objectives
- To define, describe, and forecast the epigenetics market based on offering, product, service, technology, method, application, end user (product), end user (service), and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall epigenetics market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the epigenetics market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the epigenetics market
- To benchmark players within the epigenetics market using the ‘Company Evaluation Matrix’ framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:
Geographical Analysis
- Further breakdown of the Rest of Europe epigenetics market, by country
- Further breakdown of the Rest of Asia Pacific epigenetics market, by country
- Further breakdown of the Rest of Latin America epigenetics market, by country
- Further breakdown of the Rest of Middle East epigenetics market, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Key Questions Addressed by the Report
Key players include Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), PacBio (US), Danaher (US), Merck KGaA (Germany), Active Motif, Inc. (US), Bio-Rad Laboratories, Inc. (US), Promega Corporation (US), Revvity (US), Qiagen (Germany), New England Biolabs (US), Zymo Research (US), Hologic Diagenode (US), F. Hoffmann-La Roche Ltd. (Switzerland), and Epigentek Group Inc. (US).
The kits & reagents segment held the largest market share in 2024, driven by increasing pharmaceutical investment and government support for epigenetics development.
The DNA methylation segment dominated the market in 2024 due to its effectiveness in cancer research.
The NGS (Next-Generation Sequencing) segment led the market in 2024, attributed to the growing number of companies involved in epigenetics sequencing.
The market is projected to grow from USD 2.24 billion in 2025 to USD 4.29 billion by 2030, with a CAGR of 13.9% during the forecast period.
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Epigenetics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Company
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Company
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnostics
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Схожие новости
Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 5. Источник: www.marketsandmarkets.com.